CSF2 and neuroblastoma: Treatment of high-risk NB with dinutuximab (a monoclonal antibody against GD2), either alone or in combination with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), has been shown to improve 2-year event-free survival and overall survival compared to standard treatment [11].